Immune Therapeutics, Inc. (IMUN) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2431 ALOMA AVE #124 WINTER PARK, FL 32792 |
| State of Incorp. | FL |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 150 | 3,139 | 10 | 5 | 6 | 15 | |||
| Cash and cash equivalents | 150 | 494 | 10 | 5 | 6 | 15 | |||
| Short-term investments | 2,645 | ||||||||
| Inventory, net of allowances, customer advances and progress billings | (83) | 83 | 178 | ||||||
| Inventory | (83) | 83 | 178 | ||||||
| Other undisclosed current assets | 83 | ||||||||
| Total current assets: | 150 | 3,139 | 10 | 5 | 89 | 193 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | 3 | 3 | ||||||
| Other undisclosed noncurrent assets | 813 | 0 | 0 | 0 | 0 | ||||
| Total noncurrent assets: | 813 | 0 | 1 | 3 | 3 | ||||
| TOTAL ASSETS: | 964 | 3,139 | 10 | 6 | 92 | 196 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,436 | 6,410 | 7,046 | 7,351 | 5,368 | 4,809 | |||
| Interest and dividends payable | ✕ | ✕ | 564 | 635 | |||||
| Employee-related liabilities | ✕ | ✕ | 3,421 | 3,628 | |||||
| Accounts payable | 1,300 | 2,185 | 2,563 | 2,656 | 2,065 | 2,320 | |||
| Accrued liabilities | 136 | 240 | 221 | 4,695 | 3,302 | 2,489 | |||
| Debt | 696 | 3,070 | 2,845 | 5,545 | 5,188 | 4,820 | |||
| Derivative instruments and hedges, liabilities | 1,254 | 798 | 787 | ||||||
| Due to related parties | ✕ | 395 | 891 | 531 | |||||
| Other undisclosed current liabilities | 950 | 716 | 0 | 1,670 | |||||
| Total current liabilities: | 3,477 | 11,087 | 11,677 | 13,694 | 11,342 | 11,299 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 3,477 | 11,087 | 11,677 | 13,694 | 11,342 | 11,299 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (2,513) | (7,948) | (11,667) | (13,689) | (11,251) | (6,495) | |||
| Common stock | 8 | 0 | 0 | 0 | 43 | 39 | |||
| Additional paid in capital | 380,436 | 371,474 | 371,341 | 370,908 | 369,881 | 366,625 | |||
| Accumulated deficit | (382,968) | (379,432) | (383,018) | (384,607) | (381,210) | (373,035) | |||
| Other undisclosed equity, attributable to parent | 10 | 10 | 10 | 10 | 35 | (123) | |||
| Equity, attributable to noncontrolling interest | (4,609) | ||||||||
| Total equity: | (2,513) | (7,948) | (11,667) | (13,689) | (11,251) | (11,103) | |||
| TOTAL LIABILITIES AND EQUITY: | 964 | 3,139 | 10 | 6 | 92 | 196 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 114 | |||||||
| Cost of revenue (Cost of Goods and Services Sold) | (48) | (2,092) | ||||||
| Gross profit: | 66 | (2,092) | ||||||
| Operating expenses | (1,163) | (738) | (887) | (2,838) | (4,151) | (5,914) | ||
| Other undisclosed operating income | 2,092 | |||||||
| Operating loss: | (1,163) | (738) | (887) | (2,838) | (4,085) | (5,914) | ||
| Nonoperating income (expense) | (2,373) | 4,324 | 2,476 | (559) | (4,541) | (2,020) | ||
| Investment income, nonoperating | 2,645 | 4,535 | (2,791) | |||||
| Interest and debt expense | (120) | 712 | 3,502 | (894) | (685) | 866 | ||
| Income (loss) from continuing operations: | (3,656) | 4,298 | 5,091 | (4,291) | (9,310) | (7,068) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | 4,298 | 5,091 | (4,291) | (9,310) | (7,068) | |
| Other undisclosed net income | 894 | 685 | ||||||
| Net income (loss): | (3,656) | 4,298 | 5,091 | (3,397) | (8,626) | (7,068) | ||
| Net income attributable to noncontrolling interest | 450 | |||||||
| Other undisclosed net income (loss) attributable to parent | 120 | (712) | (3,502) | (866) | ||||
| Net income (loss) attributable to parent: | (3,536) | 3,586 | 1,589 | (3,397) | (8,175) | (7,934) | ||
| Other undisclosed net income available to common stockholders, basic | 618 | |||||||
| Net income (loss) available to common stockholders, basic: | (3,536) | 3,586 | 1,589 | (3,397) | (8,175) | (7,316) | ||
| Dilutive securities, effect on basic earnings per share | 142 | |||||||
| Net income (loss) available to common stockholders, diluted: | (3,536) | 3,586 | 1,731 | (3,397) | (8,175) | (7,316) | ||
Comprehensive Income ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (3,656) | 4,298 | 5,091 | (3,397) | (8,626) | (7,068) | ||
| Comprehensive income (loss): | (3,656) | 4,298 | 5,091 | (3,397) | (8,626) | (7,068) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 450 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (3,656) | 4,298 | 5,091 | (3,397) | (8,175) | (7,068) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.